Applied Molecular Transport (Applied Molecular Transport) Debt-to-Equity : 0.08 (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Applied Molecular Transport Debt-to-Equity?

Applied Molecular Transport's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $1.35 Mil. Applied Molecular Transport's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.00 Mil. Applied Molecular Transport's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $16.24 Mil. Applied Molecular Transport's debt to equity for the quarter that ended in Sep. 2023 was 0.08.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Applied Molecular Transport's Debt-to-Equity or its related term are showing as below:

AMTI' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.08 Max: 0.97
Current: 0.08

During the past 5 years, the highest Debt-to-Equity Ratio of Applied Molecular Transport was 0.97. The lowest was 0.00. And the median was 0.08.

AMTI's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.15 vs AMTI: 0.08

Applied Molecular Transport Debt-to-Equity Historical Data

The historical data trend for Applied Molecular Transport's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Applied Molecular Transport Debt-to-Equity Chart

Applied Molecular Transport Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

0.01

0.24

0.59

Applied Molecular Transport Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-Equity	Get a 7-Day Free Trial															0.47	0.59	0.97	0.08	0.08

Competitive Comparison of Applied Molecular Transport's Debt-to-Equity

For the Biotechnology subindustry, Applied Molecular Transport's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Applied Molecular Transport's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Applied Molecular Transport's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Applied Molecular Transport's Debt-to-Equity falls into.

Applied Molecular Transport Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Applied Molecular Transport's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.844	+	31.277)	/	60.838
	=	0.59

Applied Molecular Transport's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.353	+	0)	/	16.24
	=	0.08

Applied Molecular Transport (NAS:AMTI) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Applied Molecular Transport Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Applied Molecular Transport's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Applied Molecular Transport (Applied Molecular Transport) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Applied Molecular Transport Inc (NAS:AMTI) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

450 East Jamie Court, South San Francisco, CA, USA, 94080

Website

https://www.appliedmt.com

Applied Molecular Transport Inc is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to design and develop a pipeline of novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. Its proprietary technology platform allows it to exploit existing natural cellular trafficking pathways to facilitate the active transport of therapeutic payloads across the intestinal epithelium (IE) barrier. Its product candidate, AMT-101, is an oral IL-10 fusion protein that has been designed for active transport across the IE barrier into local GI tissue. IL-10 is a potent immunomodulatory cytokine that is known to be the master regulator of immune homeostasis, including within GI mucosal tissue.

Executives

Shawn Cross	officer: Chief Financial Officer	1825 K STREET SUITE 510, WASHINGTON DC 20006
Mahmood Tahir Ph.d.	director, officer: Chief Executive Officer	1 TOWER PLACE, SUITE 850, SOUTH SAN FRANCISCO CA 94080
Brandon Hants	officer: VP, Finance & Bus. Ops.	1 TOWER PLACE, SUITE 850, SOUTH SAN FRANCISCO CA 94080
Douglas A. Rich	officer: Chief Technical Officer	C/O KYTHERA BIOPHARMACEUTICALS, INC., 30930 RUSSELL RANCH ROAD, 3RD FLOOR, WESTLAKE VILLAGE CA 91362
Bittoo Kanwar	officer: Chief Medical Officer	1 TOWER PLACE, SUITE 850, SOUTH SAN FRANCISCO CA 94080
Mrsny Randall Ph.d.	director, officer: Chief Scientific Officer	1 TOWER PLACE, SUITE 850, SOUTH SAN FRANCISCO CA 94080
Aaron Vandevender	director	1 TOWER PLACE, SUITE 850, SOUTH SAN FRANCISCO CA 94080
David Lamond	director	C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Epiq Capital Group, Llc	other: Managing member of 10% owner	ONE LOMBARD STREET, SUITE 200, SAN FRANCISCO CA 94111
Chad Boeding	other: CEO of Managing Member	ONE LOMBARD STREET, SUITE 200, SAN FRANCISCO CA 94111
Charlene A. Banard	director	C/O APPLIED MOLECULAR TRANSPORT INC., 450 EAST JAMIE COURT, SOUTH SAN FRANCISCO CA 94080
John W Smither	director	C/O KYTHERA BIOPHARMACEUTICALS, INC., 27200 WEST AGOURA ROAD, SUITE 200, CALABASAS CA 91301
Epq Llc Amt Ps	other: Owner	9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Epq Llc, Amtc Ps	other: Owner	9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Epq Llc, Amtb Ps	10 percent owner	9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521